Page 340 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.14. Treatment characteristics—changes in treatment patterns over time (continued)
Author Database Treatment 1980- 1985-89 1990-94 1995- 2000-04 2005- Statistical Notes
Year 84 99 10 analysis
PMID
74
Mettlin NCDB No Tx 39.1% 20.6% NR Total cases =
1995 PT 11.4% 29.1% 52596 in 1987
8625214 RT 27.6% 31.0%
ADT 14.8% 11.4%
Combo & other 7.2% 7.8%
(1987) (1992)
75
Mettlin NCDB RP 31.6% 34.1% NR
1998 EBRT 30.1% 26.3%
9781963 BT 1.4% 2.2%
ADT 12.0% 11.7%
Other 4.9% 4.1%
No treatment 20.0% 21.6%
(1992) (1995)
91
Mettlin NCDB BT 1.4% 3.0% NR All prostate
1999 EBRT 32.5% 26.3% cancer
10547563 RP 31.5% 36.3%
Hormone 16.8% 22.8%
No treatment 20.0% 20.8%
b
Other 8.5% 6.9%
(1992) (1996)
77
Hamilton POCS, NCI BT (only) 8.5% 12.3% NR
2011 BT+EBRT 6.4% 5.4%
20735387 EBRT (only) 19.0 20.1%
RP 45.8% 44.7%
PADT 7.6% 8.5%
WW 12.6% 9.0%
(1998) (2002)
Ordering of the studies follows Appendix Table C1.1.
5α-RI = 5α-reductase inhibitor; ADT = androgen deprivation therapy; AS = active surveillance; CAPRA = Cancer of the Prostate Risk Assessment; diff. = differentiated; OR =
odds ratio; EM = expectant management; PMID = PubMed identification number; RP = radical prostatectomy; RT = radiation therapy; TURP = transurethral resection of the
prostate; Tx = treatment; WW = watchful waiting.

b Includes subtotal prostatectomy, chemotherapy, immunotherapy, radioisotope, and unspecified treatments or combinations.

C-88